| |||||||||||||||||||
Type Coisogenic; Congenic; Mutant Strain; Targeted Mutation; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Background Strain NOD/MrkTac Donor Strain D3 (129S2/SvPas) H2 Haplotype g7 Generation N10F7+N1F6p
Generation DefinitionsDonating Investigator George Eisenbarth, U of Colorado Appearance
albino, pink eyed
Related Genotype: A/A Tyrc/TyrcDescription
Transgenic mice reportedly express the mutant Ins2*Y16A protein in the pancreatic islets and thymus. The donating investigator reports approximately 75% of female transgenic mice (founder line B) become diabetic in the presence of native insulin genes by 35 weeks of age. In contrast, NOD female transgenic mice lacking both Ins1 and Ins2 fail to produce insulin autoantibodies, and neither diabetes nor insulitis develops by 26 weeks of age. Sialitis does occur, however. Line B transgenics have lower expression levels than line F (see Stock No. 005525), and 50% of the line B male transgenics lacking both Ins1 and Ins2 develop metabolic diabetes, with little to no insulitis, before 10 weeks of age.This strain is useful to study insulin-reactive autoimmunity.
Development
In the transgenic construct the rat insulin 7 promoter is fused to a mutated preproinsulin II cDNA encoding a tyrosine to alanine amino acid substitution at position 16 of the b chain. This transgene was microinjected directly into NOD/MrkTac oocytes (Nakayama et al, 2004). Offspring from the founder line B was further crossed to NOD.Ins1-/- and NOD.Ins2-/- to generate this double mutant, transgenic strain In 2006, the T1DR received the double mutant transgenic strain at generation N10F7.
| Control | ||
|---|---|---|
| None Available | ||
| Considerations for Choosing Controls | ||
Strains carrying Ins1tm1Jja allele
005035 NOD.129S2(B6)-Ins1tm1Jja/GseJ 005525 NOD.Cg-Tg(Ins2*Y16A)3Ell Ins1tm1Jja Ins2tm1Jja/GseJ View Strains carrying Ins1tm1Jja (2 strains)
Strains carrying Ins2tm1Jja allele
005036 NOD.129S2(B6)-Ins2tm1Jja/GseJ 005525 NOD.Cg-Tg(Ins2*Y16A)3Ell Ins1tm1Jja Ins2tm1Jja/GseJ View Strains carrying Ins2tm1Jja (2 strains)
Strains carrying Tg(Ins2*Y16A)1Ell allele
005522 NOD-Tg(Ins2*Y16A)1Ell/GseJ View Strains carrying Tg(Ins2*Y16A)1Ell (1 strain)
Strains carrying other alleles of Ins1
006864 B6.Cg-Tg(Ins1-EGFP)1Hara/J 007800 FVB/N-Tg(Ins1-luc)VUPwrs/J 005352 NOD.129-(D19Mit10-D19Mit54)/GseJ 008173 NOD.Cg-Tg(Ins1-EGFP)1Hara/QtngJ 006784 STOCK Tg(Ins1-Cerulean)24Hara/J 006866 STOCK Tg(Ins1-DsRed*T4)32Hara/J View Strains carrying other alleles of Ins1 (6 strains)
Strains carrying other alleles of Ins2
View Strains carrying other alleles of Ins2 (60 strains)
View Related Disease (OMIM) Terms
Related Disease (OMIM) Terms provided by MGI
- No similarity to the expected human disease phenotype was found. One or more human genes are associated with this human disease. The mouse genotype may involve mutations to orthologs of one or more of these genes, but the phenotype did not resemble the disease.
Diabetes Mellitus, Insulin-Dependent; IDDM
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested. Diabetes Mellitus, Insulin-Dependent, 2 (INS)
Diabetes Mellitus, Permanent Neonatal; PNDM (INS)
Insulin; INS (INS)
Maturity-Onset Diabetes of the Young, Type 10; MODY10 (INS)
View Mammalian Phenotype Terms
Mammalian Phenotype Terms provided by MGI
assigned by genotype
Ins1tm1Jja/Ins1tm1Jja Ins2tm1Jja/Ins2tm1Jja Tg(Ins2*Y16A)1Ell/0
NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)1Ell
- homeostasis/metabolism phenotype
- increased circulating glucose level
- male transgenic mice lacking both native insulin genes develop diabetes before 10 weeks of age (2 consecutive measurements of >250 mg/dl glucose) (MGI Ref ID J:98583)
- immune system phenotype
- decreased susceptibility to autoimmune diabetes
- female transgenic mice lacking both native insulin genes do not exhibit diabetes by 30 weeks of age (MGI Ref ID J:98583)
- salivary gland inflammation
- at 26 weeks of age, sialitis is observed but not insulitis (MGI Ref ID J:98583)
- endocrine/exocrine gland phenotype
- salivary gland inflammation
- at 26 weeks of age, sialitis is observed but not insulitis (MGI Ref ID J:98583)
- digestive/alimentary phenotype
- salivary gland inflammation
- at 26 weeks of age, sialitis is observed but not insulitis (MGI Ref ID J:98583)
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Ins1tm1Jja relatedDiabetes and Obesity Research
Insulin Receptors and Growth Factors
Type 1 Diabetes (IDDM) Analysis Strains
NOD Transgenics
NOD/ShiLtJ Non-MHC Congenics
Immunology, Inflammation and Autoimmunity Research
Autoimmunity
Type 1 Diabetes
autoimmune pancreatitis and sialoadenitis
Research Tools
Diabetes and Obesity Research
Ins2tm1Jja relatedDiabetes and Obesity Research
Impaired Insulin Processing
Insulin Receptors and Growth Factors
Type 1 Diabetes (IDDM)
Impaired Insulin Processing
Insulin Receptors and Growth Factors
Type 1 Diabetes (IDDM)
| Allele Symbol | Ins1tm1Jja | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, Jacques Jami | ||
| Allele Type | Targeted (knock-out) | ||
| Common Name(s) | Ins1-; | ||
| Mutation Made By | Jacques Jami, INSERM | ||
| Strain of Origin | 129S2/SvPas | ||
| ES Cell Line Name | D3 | ||
| ES Cell Line Strain | 129S2/SvPas | ||
| Gene Symbol and Name | Ins1, insulin I | ||
| Chromosome | 19 | ||
| Gene Common Name(s) | Ins-1; Ins2-rs1; insulin 2, related sequence 1; insulin I or insulin pseudogene; | ||
| Molecular Note | The majority of the coding region was replaced with a neomycin selection cassette. RT-PCR analysis showed an absence of transcript in homozygous mutant mice. [MGI Ref ID J:40377] | ||
| Allele Symbol | Ins2tm1Jja | ||
| Allele Name | targeted mutation 1, Jacques Jami | ||
| Allele Type | Targeted (Reporter) | ||
| Common Name(s) | Ins2-; proins-2-; proinsulin 2-; | ||
| Mutation Made By | Jacques Jami, INSERM | ||
| Strain of Origin | 129S2/SvPas | ||
| ES Cell Line Name | D3 | ||
| ES Cell Line Strain | 129S2/SvPas | ||
| Gene Symbol and Name | Ins2, insulin II | ||
| Chromosome | 7 | ||
| Gene Common Name(s) | AA986540; IDDM2; ILPR; IRDN; Ins-2; InsII; MODY10; Mody; Mody4; expressed sequence AA986540; maturity onset diabetes of the young; maturity onset diabetes of the young 4; | ||
| Molecular Note | The majority of the coding region was replaced by the insertion of a lacZ-neo fusion gene. The expression of lacZ was found to be under the control of the endogenous promoter via cytochemical assays. [MGI Ref ID J:40377] | ||
| Allele Symbol | Tg(Ins2*Y16A)1Ell | ||
| Allele Name | transgene insertion 1, John F Elliot | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | tg B:16 alanine, line B; | ||
| Mutation Made By | John Elliott, University of Alberta | ||
| Strain of Origin | NOD/MrkTac | ||
| Expressed Gene | Ins2, insulin 2, rat | ||
| Promoter | Ins2, insulin 2, rat | ||
| Molecular Note | This transgenic construct contains the rat insulin7 construct of the rat insulin 2 gene fused to a mutated preproinsulin II cDNA where the tyrosine at position 16 of the B chain was replaced with alanine. The transgene is expressed in pancreatic beta cells. [MGI Ref ID J:97755] | ||
Genotyping Protocols
Ins2tm1Jjaalternate1, Separated PCR
Ins1tm1Jja, Separated PCR
Ins2tm1Jja, Standard PCR
Tg(Ins2*Y16A), Standard PCR
Helpful Links
Genotyping resources and troubleshooting
Nakayama M; Moriyama H; Abiru N; Babu SR; Sikora K; Li M; Miao D; Hutton JC; Elliott JF; Eisenbarth GS. 2004. Establishment of native insulin-negative NOD mice and the methodology to distinguish specific insulin knockout genotypes and a B:16 alanine preproinsulin transgene. Ann N Y Acad Sci 1037:193-8. [PubMed: 15699516] [MGI Ref ID J:97755]
Nakayama M; Abiru N; Moriyama H; Babaya N; Liu E; Miao D; Yu L; Wegmann DR; Hutton JC; Elliott JF; Eisenbarth GS. 2005. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435(7039):220-3. [PubMed: 15889095] [MGI Ref ID J:98583]
Ins1tm1Jja relatedIns2tm1Jja relatedBabaya N; Nakayama M; Moriyama H; Gianani R; Still T; Miao D; Yu L; Hutton JC; Eisenbarth GS. 2006. A new model of insulin-deficient diabetes: male NOD mice with a single copy of Ins1 and no Ins2. Diabetologia 49(6):1222-8. [PubMed: 16612590] [MGI Ref ID J:111475]
Duvillie B; Cordonnier N; Deltour L; Dandoy-Dron F; Itier JM ; Monthioux E ; Jami J ; Joshi RL ; Bucchini D. 1997. Phenotypic alterations in insulin-deficient mutant mice. Proc Natl Acad Sci U S A 94(10):5137-40. [PubMed: 9144203] [MGI Ref ID J:40377]
Duvillie B; Currie C; Chrones T; Bucchini D; Jami J; Joshi RL; Hill DJ. 2002. Increased islet cell proliferation, decreased apoptosis, and greater vascularization leading to beta-cell hyperplasia in mutant mice lacking insulin. Endocrinology 143(4):1530-7. [PubMed: 11897712] [MGI Ref ID J:106827]
Fan Y; Rudert WA; Grupillo M; He J; Sisino G; Trucco M. 2009. Thymus-specific deletion of insulin induces autoimmune diabetes. EMBO J 28(18):2812-24. [PubMed: 19680229] [MGI Ref ID J:152798]
Grupillo M; Gualtierotti G; He J; Sisino G; Bottino R; Rudert WA; Trucco M; Fan Y. 2012. Essential roles of insulin expression in Aire(+) tolerogenic dendritic cells in maintaining peripheral self-tolerance of islet beta-cells. Cell Immunol 273(2):115-23. [PubMed: 22297234] [MGI Ref ID J:181355]
Leroux L; Desbois P; Lamotte L; Duvillie B; Cordonnier N; Jackerott M; Jami J; Bucchini D; Joshi RL. 2001. Compensatory responses in mice carrying a null mutation for Ins1 or Ins2. Diabetes 50 Suppl 1:S150-3. [PubMed: 11272179] [MGI Ref ID J:77595]
Mehran AE; Templeman NM; Brigidi GS; Lim GE; Chu KY; Hu X; Botezelli JD; Asadi A; Hoffman BG; Kieffer TJ; Bamji SX; Clee SM; Johnson JD. 2012. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab 16(6):723-37. [PubMed: 23217255] [MGI Ref ID J:194167]
Mohan JF; Petzold SJ; Unanue ER. 2011. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med 208(12):2375-83. [PubMed: 22065673] [MGI Ref ID J:178627]
Moriyama H; Abiru N; Paronen J; Sikora K; Liu E; Miao D; Devendra D; Beilke J; Gianani R; Gill RG; Eisenbarth GS. 2003. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci U S A 100(18):10376-81. [PubMed: 12925730] [MGI Ref ID J:85309]
Moriyama H; Nagata M; Arai T; Okumachi Y; Yamada K; Kotani R; Yasuda H; Hara K; Yokono K. 2007. Insulin as a T cell antigen in type 1 diabetes supported by the evidence from the insulin knockout NOD mice. Diabetes Res Clin Pract 77 Suppl 1:S155-60. [PubMed: 17459508] [MGI Ref ID J:136741]
Nakayama M; Abiru N; Moriyama H; Babaya N; Liu E; Miao D; Yu L; Wegmann DR; Hutton JC; Elliott JF; Eisenbarth GS. 2005. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435(7039):220-3. [PubMed: 15889095] [MGI Ref ID J:98583]
Nakayama M; Babaya N; Miao D; Sikora K; Elliott JF; Eisenbarth GS. 2005. Thymic expression of mutated B16:A preproinsulin messenger RNA does not reverse acceleration of NOD diabetes associated with insulin 2 (thymic expressed insulin) knockout. J Autoimmun 25(3):193-8. [PubMed: 16289958] [MGI Ref ID J:106579]
Nakayama M; Beilke JN; Jasinski JM; Kobayashi M; Miao D; Li M; Coulombe MG; Liu E; Elliott JF; Gill RG; Eisenbarth GS. 2007. Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J Clin Invest 117(7):1835-43. [PubMed: 17607359] [MGI Ref ID J:124210]
Peters J; Beechey C. 2004. Identification and characterisation of imprinted genes in the mouse. Brief Funct Genomic Proteomic 2(4):320-33. [PubMed: 15163367] [MGI Ref ID J:187438]
Schechter R; Beju D; Miller KE. 2005. The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem Biophys Res Commun 334(4):979-86. [PubMed: 16039605] [MGI Ref ID J:99957]
Tg(Ins2*Y16A)1Ell relatedAlejandro EU; Lim GE; Mehran AE; Hu X; Taghizadeh F; Pelipeychenko D; Baccarini M; Johnson JD. 2011. Pancreatic beta-cell Raf-1 is required for glucose tolerance, insulin secretion, and insulin 2 transcription. FASEB J 25(11):3884-95. [PubMed: 21817126] [MGI Ref ID J:180723]
Babaya N; Nakayama M; Moriyama H; Gianani R; Still T; Miao D; Yu L; Hutton JC; Eisenbarth GS. 2006. A new model of insulin-deficient diabetes: male NOD mice with a single copy of Ins1 and no Ins2. Diabetologia 49(6):1222-8. [PubMed: 16612590] [MGI Ref ID J:111475]
Dubois-Lafforgue D; Mogenet L; Thebault K; Jami J; Krief P; Boitard C. 2002. Proinsulin 2 knockout NOD mice: a model for genetic variation of insulin gene expression in type 1 diabetes. Diabetes 51 Suppl 3:S489-93. [PubMed: 12475795] [MGI Ref ID J:107164]
Duvillie B; Bucchini D; Tang T; Jami J; Paldi A. 1998. Imprinting at the mouse Ins2 locus: evidence for cis- and trans-allelic interactions. Genomics 47(1):52-7. [PubMed: 9465295] [MGI Ref ID J:45695]
Duvillie B; Cordonnier N; Deltour L; Dandoy-Dron F; Itier JM ; Monthioux E ; Jami J ; Joshi RL ; Bucchini D. 1997. Phenotypic alterations in insulin-deficient mutant mice. Proc Natl Acad Sci U S A 94(10):5137-40. [PubMed: 9144203] [MGI Ref ID J:40377]
Duvillie B; Currie C; Chrones T; Bucchini D; Jami J; Joshi RL; Hill DJ. 2002. Increased islet cell proliferation, decreased apoptosis, and greater vascularization leading to beta-cell hyperplasia in mutant mice lacking insulin. Endocrinology 143(4):1530-7. [PubMed: 11897712] [MGI Ref ID J:106827]
Faideau B; Briand JP; Lotton C; Tardivel I; Halbout P; Jami J; Elliott JF; Krief P; Muller S; Boitard C; Carel JC. 2004. Expression of preproinsulin-2 gene shapes the immune response to preproinsulin in normal mice. J Immunol 172(1):25-33. [PubMed: 14688305] [MGI Ref ID J:87572]
Faideau B; Lotton C; Lucas B; Tardivel I; Elliott JF; Boitard C; Carel JC. 2006. Tolerance to proinsulin-2 is due to radioresistant thymic cells. J Immunol 177(1):53-60. [PubMed: 16785498] [MGI Ref ID J:134383]
Hodish I; Absood A; Liu L; Liu M; Haataja L; Larkin D; Al-Khafaji A; Zaki A; Arvan P. 2011. In vivo misfolding of proinsulin below the threshold of frank diabetes. Diabetes 60(8):2092-101. [PubMed: 21677281] [MGI Ref ID J:186814]
Jarchum I; DiLorenzo TP. 2010. Ins2 deficiency augments spontaneous HLA-A*0201-restricted T cell responses to insulin. J Immunol 184(2):658-65. [PubMed: 19966211] [MGI Ref ID J:159429]
Jasinski JM; Yu L; Nakayama M; Li MM; Lipes MA; Eisenbarth GS; Liu E. 2006. Transgenic insulin (B:9-23) T-cell receptor mice develop autoimmune diabetes dependent upon RAG genotype, H-2g7 homozygosity, and insulin 2 gene knockout. Diabetes 55(7):1978-84. [PubMed: 16804066] [MGI Ref ID J:111874]
Lamotte L; Jackerott M; Bucchini D; Jami J; Joshi RL; Deltour L. 2004. Knock-in of diphteria toxin A chain gene at Ins2 locus: effects on islet development and localization of Ins2 expression in the brain. Transgenic Res 13(5):463-73. [PubMed: 15587270] [MGI Ref ID J:94589]
Leroux L; Desbois P; Lamotte L; Duvillie B; Cordonnier N; Jackerott M; Jami J; Bucchini D; Joshi RL. 2001. Compensatory responses in mice carrying a null mutation for Ins1 or Ins2. Diabetes 50 Suppl 1:S150-3. [PubMed: 11272179] [MGI Ref ID J:77595]
Mehran AE; Templeman NM; Brigidi GS; Lim GE; Chu KY; Hu X; Botezelli JD; Asadi A; Hoffman BG; Kieffer TJ; Bamji SX; Clee SM; Johnson JD. 2012. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab 16(6):723-37. [PubMed: 23217255] [MGI Ref ID J:194167]
Mohan JF; Petzold SJ; Unanue ER. 2011. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med 208(12):2375-83. [PubMed: 22065673] [MGI Ref ID J:178627]
Moriyama H; Abiru N; Paronen J; Sikora K; Liu E; Miao D; Devendra D; Beilke J; Gianani R; Gill RG; Eisenbarth GS. 2003. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci U S A 100(18):10376-81. [PubMed: 12925730] [MGI Ref ID J:85309]
Moriyama H; Nagata M; Arai T; Okumachi Y; Yamada K; Kotani R; Yasuda H; Hara K; Yokono K. 2007. Insulin as a T cell antigen in type 1 diabetes supported by the evidence from the insulin knockout NOD mice. Diabetes Res Clin Pract 77 Suppl 1:S155-60. [PubMed: 17459508] [MGI Ref ID J:136741]
Nakayama M; Abiru N; Moriyama H; Babaya N; Liu E; Miao D; Yu L; Wegmann DR; Hutton JC; Elliott JF; Eisenbarth GS. 2005. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435(7039):220-3. [PubMed: 15889095] [MGI Ref ID J:98583]
Nakayama M; Babaya N; Miao D; Sikora K; Elliott JF; Eisenbarth GS. 2005. Thymic expression of mutated B16:A preproinsulin messenger RNA does not reverse acceleration of NOD diabetes associated with insulin 2 (thymic expressed insulin) knockout. J Autoimmun 25(3):193-8. [PubMed: 16289958] [MGI Ref ID J:106579]
Nakayama M; Beilke JN; Jasinski JM; Kobayashi M; Miao D; Li M; Coulombe MG; Liu E; Elliott JF; Gill RG; Eisenbarth GS. 2007. Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J Clin Invest 117(7):1835-43. [PubMed: 17607359] [MGI Ref ID J:124210]
Peters J; Beechey C. 2004. Identification and characterisation of imprinted genes in the mouse. Brief Funct Genomic Proteomic 2(4):320-33. [PubMed: 15163367] [MGI Ref ID J:187438]
Schechter R; Beju D; Miller KE. 2005. The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem Biophys Res Commun 334(4):979-86. [PubMed: 16039605] [MGI Ref ID J:99957]
Thebault-Baumont K; Dubois-Laforgue D; Krief P; Briand JP; Halbout P; Vallon-Geoffroy K; Morin J; Laloux V; Lehuen A; Carel JC; Jami J; Muller S; Boitard C. 2003. Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 111(6):851-7. [PubMed: 12639991] [MGI Ref ID J:82522]
Mohan JF; Petzold SJ; Unanue ER. 2011. Register shifting of an insulin peptide-MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med 208(12):2375-83. [PubMed: 22065673] [MGI Ref ID J:178627]
Nakayama M; Abiru N; Moriyama H; Babaya N; Liu E; Miao D; Yu L; Wegmann DR; Hutton JC; Elliott JF; Eisenbarth GS. 2005. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435(7039):220-3. [PubMed: 15889095] [MGI Ref ID J:98583]
Nakayama M; Beilke JN; Jasinski JM; Kobayashi M; Miao D; Li M; Coulombe MG; Liu E; Elliott JF; Gill RG; Eisenbarth GS. 2007. Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J Clin Invest 117(7):1835-43. [PubMed: 17607359] [MGI Ref ID J:124210]
Animal Health Reports
Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.
| Pricing for USA, Canada and Mexico shipping destinations |
|
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2250.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
| Pricing for International shipping destinations |
|
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2925.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|
|
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
| Control | ||
|---|---|---|
| None Available | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
For Licensing and Use Restrictions view the link(s) below:
- Strain(s) not available to companies or for-profit entities.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.